Zacks Research Upgrades Collegium Pharmaceutical (NASDAQ:COLL) to “Strong-Buy”

Collegium Pharmaceutical (NASDAQ:COLL) was upgraded by equities research analysts at Zacks Research from a “strong sell” rating to a “strong-buy” rating in a research report issued to clients and investors on Thursday, Zacks reports.

COLL has been the subject of a number of other reports. Truist Financial initiated coverage on Collegium Pharmaceutical in a research report on Wednesday, September 9th. They set a “buy” rating and a $49.00 price objective for the company. Barclays reduced their target price on shares of Collegium Pharmaceutical from $56.00 to $48.00 and set an “overweight” rating on the stock in a report on Wednesday, August 19th. Needham & Company LLC reduced their target price on shares of Collegium Pharmaceutical from $56.00 to $46.00 and set a “buy” rating on the stock in a report on Thursday, August 6th. Wall Street Zen downgraded shares of Collegium Pharmaceutical from a “buy” rating to a “hold” rating in a research note on Saturday, August 8th. Finally, Weiss Ratings cut shares of Collegium Pharmaceutical from a “hold (c-)” rating to a “sell (d+)” rating in a report on Friday, September 4th. One equities research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, Collegium Pharmaceutical presently has a consensus rating of “Moderate Buy” and an average target price of $48.71.

Collegium Pharmaceutical Stock Up 0.0%

COLL traded up $0.01 on Thursday, hitting $23.19. 558,644 shares of the company were exchanged, compared to its average volume of 831,925. The firm has a 50-day moving average price of $24.07 and a two-hundred day moving average price of $30.84. The company has a current ratio of 1.03, a quick ratio of 0.84 and a debt-to-equity ratio of 3.32. Collegium Pharmaceutical has a twelve month low of $21.43 and a twelve month high of $50.79. The company has a market cap of $755.07 million, a price-to-earnings ratio of 18.70, a price-to-earnings-growth ratio of 0.72 and a beta of 0.73.

Collegium Pharmaceutical (NASDAQ:COLL) last posted its quarterly earnings results on Thursday, August 6th. The specialty pharmaceutical company reported $1.92 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.72 by $0.20. The company had revenue of $199.88 million for the quarter, compared to analyst estimates of $199.62 million. Collegium Pharmaceutical had a return on equity of 91.43% and a net margin of 5.93%. Collegium Pharmaceutical’s revenue for the quarter was up 6.3% compared to the same quarter last year. During the same quarter last year, the company earned $1.68 EPS. On average, equities analysts predict that Collegium Pharmaceutical will post 6.42 earnings per share for the current year.

Institutional Investors Weigh In On Collegium Pharmaceutical

Several hedge funds and other institutional investors have recently made changes to their positions in COLL. Farther Finance Advisors LLC raised its holdings in Collegium Pharmaceutical by 23.1% during the third quarter. Farther Finance Advisors LLC now owns 16,406 shares of the specialty pharmaceutical company’s stock worth $358,000 after purchasing an additional 3,082 shares in the last quarter. WINTON GROUP Ltd purchased a new stake in Collegium Pharmaceutical in the second quarter valued at $536,000. Squarepoint Ops LLC lifted its position in Collegium Pharmaceutical by 124.8% in the second quarter. Squarepoint Ops LLC now owns 47,897 shares of the specialty pharmaceutical company’s stock valued at $1,734,000 after acquiring an additional 26,589 shares during the last quarter. Corient Private Wealth LP lifted its position in Collegium Pharmaceutical by 60.5% in the second quarter. Corient Private Wealth LP now owns 71,870 shares of the specialty pharmaceutical company’s stock valued at $2,603,000 after acquiring an additional 27,097 shares during the last quarter. Finally, Amundi boosted its stake in Collegium Pharmaceutical by 188.0% in the second quarter. Amundi now owns 23,492 shares of the specialty pharmaceutical company’s stock valued at $850,000 after acquiring an additional 15,336 shares in the last quarter.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc is a specialty pharmaceutical company focused on developing, acquiring and commercializing medicines for central nervous system disorders. The company’s portfolio is concentrated in pain management and includes products for chronic and acute pain, opioid-induced constipation and related conditions.

Collegium’s marketed products include Xtampza ER, an extended-release oxycodone formulation designed with the company’s DETERx abuse-deterrent technology; Nucynta and Nucynta ER, tapentadol products for acute and chronic pain; Belbuca, a buprenorphine buccal film for chronic pain; and Symproic, a treatment for opioid-induced constipation.